Edition:
United States

Atossa Genetics Inc (ATOS.OQ)

ATOS.OQ on NASDAQ Stock Exchange Capital Market

0.31USD
3:59pm EST
Change (% chg)

$-0.01 (-3.88%)
Prev Close
$0.32
Open
$0.32
Day's High
$0.32
Day's Low
$0.31
Volume
121,831
Avg. Vol
612,484
52-wk High
$1.85
52-wk Low
$0.28

Select another date:

Tue, Nov 14 2017

BRIEF-Atossa Genetics posts Q3 loss per share ‍$0.18​

* Atossa Genetics announces third quarter 2017 financial results and provides company update

BRIEF-Iroquois Capital Management reports 9.01 pct passive stake in Atossa Genetics as of Oct 26 - SEC filing

* Iroquois Capital Management reports 9.01 pct passive stake in Atossa Genetics Inc, as of Oct 26 - SEC filing Source text: (http://bit.ly/2iIbgjU) Further company coverage:

BRIEF-Empery Asset Management reports 9.01 pct passive stake in Atossa Genetics

* Empery Asset Management LP reports 9.01 percent passive stake in Atossa Genetics as of Oct 26 - SEC filing‍​ Source text: (http://bit.ly/2z0yYCe) Further company coverage:

BRIEF-Atossa Genetics announces pricing of $5.1 million public offering

* Atossa Genetics announces pricing of $5.1 million public offering of common stock

BRIEF-Atossa Genetics announces proposed public offering of common stock

* Atossa Genetics announces proposed public offering of common stock

BRIEF-Atossa Genetics announces upcoming Phase 2 study of topical Endoxifen

* Atossa Genetics announces upcoming Phase 2 study of topical Endoxifen

BRIEF-Atossa Genetics files for mixed shelf of upto $50 million

* Atossa Genetics Inc files for mixed shelf of upto $50 million - SEC filing‍​ Source text: [http://bit.ly/2xmdyOY] Further company coverage:

BRIEF-Atossa Genetics reports Q2 ‍loss per share $0.64​

* Atossa Genetics announces second quarter 2017 financial results and provides company update

BRIEF-Atossa Genetics receives positive safety committee assessment

* Atossa genetics says received positive interim safety assessment of first cohort receiving proprietary oral endoxifen in phase 1 dose escalation study Source text for Eikon: Further company coverage:

Select another date: